Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion

PHASE1RecruitingINTERVENTIONAL
Enrollment

180

Participants

Timeline

Start Date

April 14, 2021

Primary Completion Date

December 31, 2026

Study Completion Date

March 30, 2027

Conditions
Solid Tumor
Interventions
DRUG

IDE397

IDE397 dosed orally

DRUG

Docetaxel

Intravenous infusion

DRUG

Paclitaxel

Intravenous infusion

DRUG

Sacituzumab govitecan

Intravenous infusion

Trial Locations (38)

100

RECRUITING

National Taiwan University Hospital, Taipei

704

RECRUITING

National Cheng Kung University Hospital, Tainan City

10032

RECRUITING

Columbia University Medical Center - Herbert Irving Pavilion, New York

10065

RECRUITING

Weill Cornell Medical College, New York

10408

RECRUITING

National Cancer Center, Goyang-si

13005

RECRUITING

Hôpital Timone, Marseille

20246

RECRUITING

Universitaetsklinikum Hamburg-Eppendorf (UKE), Hamburg

21287

RECRUITING

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore

28041

RECRUITING

Hospital Universitario 12 de Octubre (H12O), Madrid

28050

RECRUITING

START Madrid-HM - Centro Integral Oncológico Clara Campal (CIOCC), Madrid

28223

RECRUITING

NEXT Madrid, Universitary Hospital QuironSAlud, Madrid

28644

RECRUITING

CHA University - Bundang Medical Center, Seongnam-si

RECRUITING

Chungbuk National University Hospital, Cheongju-si

31059

RECRUITING

Institut Claudius Regaud - IUCT-Oncopole, Toulouse

32806

RECRUITING

Orlando Health Cancer Institute, Orlando

33076

RECRUITING

Institut Bergonie, Bordeaux

34747

WITHDRAWN

Advent Health, Celebration

35000

RECRUITING

Centre Eugène Marquis, Rennes

37203

RECRUITING

SCRI Oncology Partners, Nashville

40536

WITHDRAWN

Markey Cancer Center, Lexington

46009

RECRUITING

Instituto Valenciano de Oncología (IVO), Valencia

46202

COMPLETED

Indiana University Health Hospital, Indianapolis

48201

WITHDRAWN

Barbara Ann Karmanos Cancer Institute, Detroit

72205

RECRUITING

University of Arkansas for Medical Sciences, Little Rock

73104

RECRUITING

Stephenson Cancer Center, Oklahoma City

77030

RECRUITING

MD Anderson, Houston

78229

RECRUITING

Next Oncology, San Antonio

85258

COMPLETED

Honor Health Research Institute, Scottsdale

91010

RECRUITING

City of Hope, Duarte

95403

WITHDRAWN

Providence Medical Group, Santa Rosa

98104

RECRUITING

Swedish Cancer Institute, Seattle

02115

RECRUITING

Dana Farber Cancer Institute, Boston

02906

RECRUITING

LifeSpan - Brown University, Providence

02010

RECRUITING

The Kinghorn Cancer Centre, St Vincent's Health Network Sydney, Darlinghurst

05042

RECRUITING

Southern Oncology Clinical Research Unit, Bedford Park

03722

RECRUITING

Sevrance Hospital, Seoul

05505

RECRUITING

Asan Medical Center, Seoul

08035

RECRUITING

Vall Hebron Institute of Oncology, Barcelona

Sponsors

Lead Sponsor

All Listed Sponsors
lead

IDEAYA Biosciences

INDUSTRY

NCT04794699 - Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion | Biotech Hunter | Biotech Hunter